Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.

Bays HE, McKenney J, Maki KC, Doyle RT, Carter RN, Stein E.

Mayo Clin Proc. 2010 Feb;85(2):122-8. doi: 10.4065/mcp.2009.0397.

2.

Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.

Davidson MH, Ose L, Frohlich J, Scott RS, Dujovne CA, Escobar ID, Bertolami MC, Cihon F, Maccubbin DL, Mercuri M.

Clin Cardiol. 2003 Nov;26(11):509-14. Review.

3.

Comparison of statins in hypertriglyceridemia.

Stein EA, Lane M, Laskarzewski P.

Am J Cardiol. 1998 Feb 26;81(4A):66B-69B. Review.

PMID:
9526817
4.

Lipid-lowering efficacy of atorvastatin.

Adams SP, Tsang M, Wright JM.

Cochrane Database Syst Rev. 2015 Mar 12;(3):CD008226. doi: 10.1002/14651858.CD008226.pub3. Review.

PMID:
25760954
5.

Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.

Bays H.

Am J Cardiol. 2006 Aug 21;98(4A):71i-76i. Epub 2006 May 30. Review.

PMID:
16919519
6.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
7.

The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.

Backes J, Anzalone D, Hilleman D, Catini J.

Lipids Health Dis. 2016 Jul 22;15(1):118. doi: 10.1186/s12944-016-0286-4. Review.

8.

Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.

Fialkow J.

Am J Cardiovasc Drugs. 2016 Aug;16(4):229-39. doi: 10.1007/s40256-016-0170-7. Review.

9.

Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.

Barter P, Ginsberg HN.

Am J Cardiol. 2008 Oct 15;102(8):1040-5. doi: 10.1016/j.amjcard.2008.05.056. Epub 2008 Jul 31. Review. Erratum in: Am J Cardiol. 2009 Feb 1;103(3):435.

10.

Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).

Brinton EA, Mason RP.

Lipids Health Dis. 2017 Jan 31;16(1):23. doi: 10.1186/s12944-017-0415-8. Review.

11.

Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus.

Tajuddin N, Shaikh A, Hassan A.

Diabetes Metab Syndr Obes. 2016 Apr 19;9:109-18. doi: 10.2147/DMSO.S97036. eCollection 2016. Review.

12.

A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids.

Karalis DG.

Adv Ther. 2017 Feb;34(2):300-323. doi: 10.1007/s12325-016-0462-y. Epub 2016 Dec 15. Review.

13.

Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia.

Benes LB, Bassi NS, Davidson MH.

Vasc Health Risk Manag. 2016 Dec 12;12:481-490. doi: 10.2147/VHRM.S58149. eCollection 2016. Review.

14.

Supplemental Content

Support Center